Europe South Asia Asia Pacific Americas Middle East Africa BBC Homepage World Service Education

Front Page



UK Politics







Talking Point
On Air
Low Graphics

Thursday, January 28, 1999 Published at 12:09 GMT


Brain cancer pill breakthrough

Thousands of Britons develop brain tumours every year

A brain cancer drug which is as easy to take as an aspirin is being hailed as the most important advance in brain cancer treatment for 20 years.

Temozolomide, marketed as Temodal, has been granted a licence by the European Medicines Evaluation Agency and was launched in the UK on Thursday.

It will be available on the NHS from next month for adults and children with advanced brain cancer.

However, many health authorities are likely to ration it as it costs around £1,000 for a monthly course of treatment.

But because it is so easy to take, it can be taken on an outpatient basis, saving money on hospital treatment.

In tests, Temodal has been shown to boost survival rates as well as reducing the side effects of other treatments.

And experts say it could eventually have a big impact on other cancers.

The capsule-form drug treats the most common and deadly form of brain tumour, glioblastoma multiforme. This affects around 2,000 people a year in the UK.

Professor Malcolm Stevens, who helped develop the drug, says there are very few orally taken cancer drugs.

"It is much more convenient for patients," he said.

The drug was developed by the Cancer Research Campaign (CRC) in conjuction with drugs company Schering Plough.

The deal means substantial royalties from sales of the drugs will be ploughed back into the CRC's research work.

Remarkable results

Professor Gordon McVie, director general of the CRC, said the drug was "the most important advance in brain cancer treatment for the past 20 years".

[ image: Professor McVie: Temodal could revolutionise cancer care]
Professor McVie: Temodal could revolutionise cancer care
Professor Stevens was more modest, saying it remained to be seen how big the drug's impact was.

"It is a new adventure," he said, but he agreed trial results were exciting.

"There aren't any successful drug treatments for this form of brain cancer," he stated. "Only chemotherapy and radiotherapy, but they do not really do any more than buy a short period of time."

The trials were conducted on people with advanced brain cancer for whom other treatment had not worked.

"They were exceedingly ill ," said Professor Stevens. "We can only speculate on what the drug would do for people with small tumours."

He added that the drug could be used in combination with other drugs and treat other cancers.

Temodal will initially prescribed on a monthly basis and taken over five days by patients who have not responded to surgery and radiotherapy.

If it works, patients will get another monthly dosage and use it until their cancer recedes.

Temodal works by damaging DNA in brain cancer cells and causing them to commit suicide.

Non-cancerous cells are not harmed and, unlike most cancer treatments, it can filter through the brain's protective barrier.

Compassionate grounds

It is the first of the CRC's drugs to be given to patients on compassionate grounds before it was granted a licence.

This was due to the "very positive results" it obtained in preliminary trials.

The drug was among a batch of chemicals which were synthesised in the late 70s at Birmingham's Aston University.

Further trials will now be carried out on the drug to see if it can also treat malignant melanoma, the most serious form of skin cancer, and other types of brain cancer.

Advanced options | Search tips

Back to top | BBC News Home | BBC Homepage | ©

Health Contents

Background Briefings
Medical notes

Relevant Stories

05 Jan 99†|†Health
Dental risk for cancer children

05 Jan 99†|†Health
Hopes for gentler cancer treatment

28 Jan 99†|†Health
A million celebrate life after the Big C

03 Dec 98†|†Health
A brave new dawn for medicine

Internet Links

Cancer Research Campaign

Schering Plough


The BBC is not responsible for the content of external internet sites.

In this section

Disability in depth

Spotlight: Bristol inquiry

Antibiotics: A fading wonder

Mental health: An overview

Alternative medicine: A growth industry

The meningitis files

Long-term care: A special report

Aids up close

From cradle to grave

NHS reforms: A guide

NHS Performance 1999

From Special Report
NHS in crisis: Special report

British Medical Association conference '99

Royal College of Nursing conference '99